Physician profile
Ronak Chaudhari
NPI 1861798431
$20,287.07
in general payments reported to CMS, 2019-2025
59 companies · $3,887 in 2025
The $3,887 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $2,391 · 2021: $2,681 · 2022: $2,440 · 2023: $3,136 · 2024: $3,389 · 2025: $3,887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $175 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,110.81 |
| Consulting Fee | $175.00 |
| Education | $126.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,351.16 | 2019-2025 | Repatha, Tepezza, Repatha |
| Novo Nordisk INC | $2,014.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,914.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,343.99 | 2019-2025 | Jardiance, Tradjenta |
| Corcept Therapeutics | $1,204.47 | 2019-2025 | Korlym |
| Mannkind Corporation | $1,112.64 | 2020-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $763.86 | 2023-2025 | |
| Amarin Pharma, INC. | $701.00 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $698.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $685.66 | 2022-2025 | |
| Medtronic, INC. | $637.71 | 2021-2025 | Minimed 780g, Guardian Sensor (3), Minimed 770g |
| Abbvie INC. | $575.50 | 2019-2025 | Ubrelvy |
| Xeris Pharmaceuticals, INC. | $550.36 | 2020-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Insulet Corporation | $541.22 | 2019-2025 | Omnipod |
| Abbott Laboratories | $527.41 | 2019-2025 | Freestyle Libre 3 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $337.94 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Radius Health, INC. | $313.49 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $300.04 | 2019-2023 | Steglatro, Steglujan |
| Dexcom, INC. | $250.99 | 2019-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $214.53 | 2021-2025 | Isturisa |
| Kowa Pharmaceuticals America, INC. | $211.00 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $182.89 | 2021-2024 | Unithroid |
| Kyowa Kirin, INC. | $179.14 | 2023-2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $167.47 | 2019-2020 | |
| Sequel Med Tech, LLC | $154.46 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $145.30 | 2019-2025 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $124.24 | 2020-2022 | |
| Esperion Therapeutics, INC. | $116.63 | 2021-2025 | Nexletol |
| Genzyme Corporation | $105.00 | 2019 | |
| Horizon Therapeutics Plc | $98.70 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $98.20 | 2025 | Yorvipath |
| Shire North American Group INC | $91.70 | 2019 | |
| Ascensia Diabetes Care US INC. | $89.25 | 2023-2025 | |
| Beta Bionics, INC. | $84.46 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ultragenyx Pharmaceutical INC. | $78.01 | 2021-2022 | |
| Amphastar Pharmaceuticals, INC. | $73.75 | 2024-2025 | |
| Antares Pharma, INC. | $72.26 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Regeneron Healthcare Solutions, INC. | $65.76 | 2019-2020 | |
| Rgh Enterprises LLC | $65.46 | 2025 | |
| Chiesi USA, INC. | $59.73 | 2024-2025 | Mycapssa, Myalept |
| Ibsa Pharma INC. | $58.22 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $57.23 | 2024-2025 | |
| Medtronic Minimed, INC. | $56.63 | 2019-2020 | |
| Cequr Corporation | $54.33 | 2024-2025 | Cequr Simplicity |
| Pfizer INC. | $53.65 | 2023-2024 | |
| Amryt Pharma Holdings LTD | $50.33 | 2020-2022 | |
| Valeritas, INC. | $47.92 | 2019 | |
| Madrigal Pharmaceuticals | $43.74 | 2025 | Rezdiffra |
| Alvogen INC | $37.62 | 2025 | Teriparatide |
| Almatica Pharma LLC | $32.07 | 2025 | Teriparatide |
| Halozyme INC | $29.31 | 2023 | |
| Becton, Dickinson and Company | $28.84 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $26.59 | 2025 | Imcivree |
| Verity Pharmaceuticals INC. | $18.69 | 2024 | Tlando |
| Acella Pharmaceuticals, LLC | $18.44 | 2025 | NP Thyroid 60 |
| Tolmar, INC. | $18.30 | 2025 | Jatenzo |
| Zealand Pharma US, INC. | $14.41 | 2020 | |
| Senseonics, Incorporated | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronak Chaudhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.